0001209191-19-046150.txt : 20190815 0001209191-19-046150.hdr.sgml : 20190815 20190815163347 ACCESSION NUMBER: 0001209191-19-046150 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190815 FILED AS OF DATE: 20190815 DATE AS OF CHANGE: 20190815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mahatme Sandesh CENTRAL INDEX KEY: 0001511034 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 191030674 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-08-15 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001511034 Mahatme Sandesh 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 0 1 0 0 EVP, CFO & CBO Common Stock 2019-08-15 4 M 0 2863 34.92 A 23288 D Common Stock 2019-08-15 4 M 0 3021 29.03 A 26309 D Common Stock 2019-08-15 4 M 0 2625 13.90 A 28934 D Common Stock 2019-08-15 4 M 0 985 13.71 A 29919 D Common Stock 2019-08-15 4 M 0 260 13.71 A 30179 D Common Stock 12012 I By trust Stock option (right to buy) 34.92 2019-08-15 4 M 0 2863 0.00 D 2014-06-04 2023-06-04 Common Stock 2863 0 D Stock option (right to buy) 29.03 2019-08-15 4 M 0 3021 0.00 D 2015-02-28 2024-02-28 Common Stock 3021 0 D Stock option (right to buy) 13.90 2019-08-15 4 M 0 2625 0.00 D 2016-02-27 2025-02-27 Common Stock 2625 0 D Stock option (right to buy) 13.71 2019-08-15 4 M 0 985 0.00 D 2017-02-28 2026-02-28 Common Stock 985 2385 D Stock option (right to buy) 13.71 2019-08-15 4 M 0 260 0.00 D 2017-02-28 2026-02-28 Common Stock 260 218 D The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. /s/ David Tyronne Howton, as Attorney-in-Fact for Sandesh Mahatme 2019-08-15